Ivan Kairatov is a distinguished biopharma expert with a deep background in research and development, specifically focusing on the evolution of oncological therapies and high-tech drug delivery systems. He has spent years analyzing how technological shifts in molecular engineering redefine patient
The fundamental question of how a single fertilized egg transforms into a complex human being with trillions of specialized cells remains one of the greatest mysteries in modern biology. For decades, scientists relied on animal models like mice or zebrafish to approximate these processes, but these
Ivan Kairatov joins us to discuss the shifting landscape of hematologic oncology, bringing his deep expertise in biopharmaceutical innovation to the forefront of the conversation. As a researcher who has spent years navigating the complex pathways of drug development, Kairatov offers a unique
The traditional methodology of identifying genetic mutations in cancer patients often relies on time-consuming processes that destroy precious biopsy samples before a treatment plan can even begin. This fundamental conflict between diagnostic necessity and sample preservation has led to the
For decades, the pursuit of a cure for Alzheimer’s disease has been defined by a series of high-profile clinical failures and a mounting sense of urgency as global populations age at an unprecedented rate. This persistent medical wall has historically been reinforced by the sheer volume of
The staggering reality that nearly ninety percent of pharmaceutical candidates fail during clinical trials has forced a fundamental reckoning within the global research community. For many decades, the industry relied almost exclusively on animal models to predict the efficacy and safety of new
